TOPⅡ聯合Ki-67和p53表達對局部晚期乳腺癌化療敏感性的預測分析_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 李紅生 ¹ , 羅麗瓊 ¹ , 馬永錄 ¹ , 田君才 ² , 戴偉平 ²

1. ;
2. ;

Corresponding?author：

李紅生, Email: 745279057@qq.com

Keywords：

乳腺腫瘤; 治療; 拓撲異構酶Ⅱ; p53基因; 增生細胞核抗原

DOI：

10.7507/1007-9424.20150026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的探討TOPⅡ聯合p53和Ki-67的表達對局部晚期乳腺癌化療敏感性的預測價值。方法采用免疫組化方法檢測90例乳腺癌患者不同分子分型的TOPⅡ、p53和Ki-67的表達狀況，比較不同TOPⅡ、p53及Ki-67表達狀況患者接受新輔助化療的療效差異。結果 Ki-67表達陽性率在HER2過表達型、Basal-like型、腺腔A型和腺腔B型之間的差異具有統計學意義（χ²=38.877，P=0.000），其中HER2過表達型和Basal-like型高于腺腔A型和腺腔B型；TOPⅡ及p53的表達表達陽性率在4種分子分型間的差異無統計學意義（χ²=7.105，P=0.069；χ²=7.105，P=0.069）。TOPⅡ和Ki-67表達陽性者的新輔助化療療效優于表達陰性者χ²=18.28，P=0.000；χ²=6.64，P=0.009；而p53的表達狀況與新輔助化療的敏感性無關。結論 HER2過表達型和Basal-like型乳腺癌患者對新輔助化療敏感，療效好；TOPⅡ表達陽性并Ki-67表達陽性可作為乳腺癌臨床化療患者敏感性生物學指標。

Citation： 李紅生, 羅麗瓊, 馬永錄, 田君才, 戴偉平. TOPⅡ聯合Ki-67和p53表達對局部晚期乳腺癌化療敏感性的預測分析. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(1): 102-105. doi: 10.7507/1007-9424.20150026 Copy

1.	Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol, 2011, 22(8):1736-1747.
2.	楊雪寧, 吳一龍.實體瘤治療評價標準-RECIST.循證醫學, 2004, 4(2):85-90.
3.	孫立婷, 郭麗英.Ki-67抗原與乳腺癌的相關性研究.中國普外基礎與臨床雜志, 2014, 21(5):650-653.
4.	張繼運, 沙新海, 于明濤.C-erbB-2、p53、Ki-67及VEGF在乳腺癌中的表達及相關性.實用癌癥雜志, 2012, 27(3):241-243.
5.	王躍華, 李建民, 李麗, 等.乳腺癌組織中拓撲異構酶Ⅱα基因的檢測及臨床應用.診斷病理學雜志, 2010, 17(6):416-419.
6.	Berger JM, Gamblin SJ, Harrison SC, et al.Structure and mechanism of DNA topoismeraseⅡ.Nature, 1996, 379(6562):225-232.
7.	Harris LN, Yang L, Tang C, et al.Induction of sensitiyity to Doxorubicin and Etoposide by transfection of MCF-7 breast cancer cells with heregulinβ-2.Clin Cancer Ras, 1998, 4(4):1005-1012.
8.	Durbecq V, Paesmans M, Cardose F, et al.Topoisomerase-Ⅱalpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.Mol Cancre Ther, 2004, 3(10):1207-1214.
9.	Di LA, Gancberg D, Larsimont D, et al.HER-2 amplification and topoisomerase-Ⅱalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Clin Cancer Res, 2002, 8(5):1107-1116.
10.	劉春萍, 逯翀, 田源, 等.乳腺癌Her-2與TOP2A基因表達對新輔助化療效果的預測價值.中國普通外科雜志, 2010, 19(11):1200-1203.
11.	吳一萍, 曹曉智.CerbB-2、p53、ER和PR受體在乳腺癌組織中的表達及意義.中國腫瘤臨床與康復, 2009, 16(2):105-107.
12.	劉建誠, 姜忠敏, 李新, 等.maspin和p53在乳腺癌中的表達及臨床意義.中國普外基礎與臨床雜志, 2013, 20(5):547-550.
13.	Rahmanzadeh R, Rai P, Celli JP, et al.ki-67 a molecular target for therapy in an in vitro three-dimensional model for o-varian cancer.Cancer Res, 2010, 70(22):9234-9242.
14.	朱學強, 任剛, 胡洪林.乳腺癌組織中VEGF、CerbB-2、p53、Ki67的表達及臨床意義.西部醫學, 2009, 21(3):427-429.
15.	張麗, 曾梅, 田林, 等.Cyclin D1、Ki-67及PTEN在乳腺癌中的表達及意義.現代腫瘤醫學, 2013, 21(8):1772-1774.
16.	Carey LA, Dees EC, Sawyer L, et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res, 2007, 15(13):2329-2334.

1. Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol, 2011, 22(8):1736-1747.
2. 楊雪寧, 吳一龍.實體瘤治療評價標準-RECIST.循證醫學, 2004, 4(2):85-90.
3. 孫立婷, 郭麗英.Ki-67抗原與乳腺癌的相關性研究.中國普外基礎與臨床雜志, 2014, 21(5):650-653.
4. 張繼運, 沙新海, 于明濤.C-erbB-2、p53、Ki-67及VEGF在乳腺癌中的表達及相關性.實用癌癥雜志, 2012, 27(3):241-243.
5. 王躍華, 李建民, 李麗, 等.乳腺癌組織中拓撲異構酶Ⅱα基因的檢測及臨床應用.診斷病理學雜志, 2010, 17(6):416-419.
6. Berger JM, Gamblin SJ, Harrison SC, et al.Structure and mechanism of DNA topoismeraseⅡ.Nature, 1996, 379(6562):225-232.
7. Harris LN, Yang L, Tang C, et al.Induction of sensitiyity to Doxorubicin and Etoposide by transfection of MCF-7 breast cancer cells with heregulinβ-2.Clin Cancer Ras, 1998, 4(4):1005-1012.
8. Durbecq V, Paesmans M, Cardose F, et al.Topoisomerase-Ⅱalpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.Mol Cancre Ther, 2004, 3(10):1207-1214.
9. Di LA, Gancberg D, Larsimont D, et al.HER-2 amplification and topoisomerase-Ⅱalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Clin Cancer Res, 2002, 8(5):1107-1116.
10. 劉春萍, 逯翀, 田源, 等.乳腺癌Her-2與TOP2A基因表達對新輔助化療效果的預測價值.中國普通外科雜志, 2010, 19(11):1200-1203.
11. 吳一萍, 曹曉智.CerbB-2、p53、ER和PR受體在乳腺癌組織中的表達及意義.中國腫瘤臨床與康復, 2009, 16(2):105-107.
12. 劉建誠, 姜忠敏, 李新, 等.maspin和p53在乳腺癌中的表達及臨床意義.中國普外基礎與臨床雜志, 2013, 20(5):547-550.
13. Rahmanzadeh R, Rai P, Celli JP, et al.ki-67 a molecular target for therapy in an in vitro three-dimensional model for o-varian cancer.Cancer Res, 2010, 70(22):9234-9242.
14. 朱學強, 任剛, 胡洪林.乳腺癌組織中VEGF、CerbB-2、p53、Ki67的表達及臨床意義.西部醫學, 2009, 21(3):427-429.
15. 張麗, 曾梅, 田林, 等.Cyclin D1、Ki-67及PTEN在乳腺癌中的表達及意義.現代腫瘤醫學, 2013, 21(8):1772-1774.
16. Carey LA, Dees EC, Sawyer L, et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res, 2007, 15(13):2329-2334.

Previous Article
急性胰腺炎的綜合治療
Next Article
射頻消融行保脾手術治療體會（附24例報道）

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

TOPⅡ聯合Ki-67和p53表達對局部晚期乳腺癌化療敏感性的預測分析

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content